cardioКардиологияKardiologiia0022-90402412-5660Kardiomag10.18087/cardio.n680cardio-680Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИRESEARCH ARTICLESВлияние терапии полиненасыщенными жирными кислотами на смертность от ишемической болезни сердца. Мета-анализAssociation of polyunsaturated fatty acids treatment with coronary mortality. A meta-analysishttps://orcid.org/0000-0001-9159-6177ПлавинскийС. Л.PlavinskiiS. L.

191015, Санкт-Петербург, ул. Кирочная, 41

SPIN-код: 5660-4661

Kirochnaya 41, St.-Petersburg 191015

SPIN-code: 5660-4661

s.plavinskij@szgmu.ruhttps://orcid.org/0000-0001-8215-086XБариноваА. Н.BarinovaA. N.

191015, Санкт-Петербург, ул. Кирочная, 41

SPIN-код: 2010-4354

Kirochnaya 41, St.-Petersburg 191015

SPIN code: 2010-4354

Anna.Barinova@szgmu.ruhttps://orcid.org/0000-0002-6955-0145ДанишевскийК. Д.DanishevskiK. D.

101000, г. Москва, ул. Мясницкая, 20

SPIN-код: 3038-7167

Myasnitskaya str., 20, Moscow 101000

SPIN code: 3038-7167

7908046@gmail.comФГБОУ ВО «Северо-Западный государственный медицинский университет им. И. И. Мечникова» МЗ РФРоссия“I. I. Mechnikov North-West State Medical University” Ministry of Health of the Russian FederationRussian FederationНИУ «Высшая школа экономики»РоссияNational Research University Higher School of EconomicsRussian Federation2019301020195911S6368Copyright © Kardiomag, 20192019KardiomagKardiomaghttps://cardio.elpub.ru/jour/about/submissions#copyrightNoticehttps://cardio.elpub.ru/jour/article/view/680

Цель. Проведено мета-аналитическое суммирование данных по влиянию терапии длинноцепочечными полиненасыщенными жирными кислотами на смертность от ишемической болезни сердца (ИБС). Методы. В анализ включены только исследования с более чем 500 участниками и продолжительностью более года. Всего в мета-анализ включены 13 исследований с общим числом участников 127455 человек. Результаты. Суммарная модель с фиксированными факторами указывала на значимое снижение вероятности смерти от ИБС в группе, получавшей терапию полиненасыщенными жирными кислотами (отношение шансов (ОШ) 0,89, 95% доверительный интервал (ДИ): 0,83–0,95, р=0,001). Модель со случайными факторами также давала доверительный интервал, не пересекавший единицу (ОШ 0,88, 95% ДИ: 0,80–0,97, p=0,008). Выделение группы исследований, в которых назначалась терапия эйкозопентаеновой кислотой в дозе 460 мг и докозогексаеновой кислотой в дозе 380 мг, показало значимое снижение смертности (ОШ 0,84, 95% ДИ: 0,77–0,92, p<0,001) в обеих моделях – как со случайными, так и с фиксированными факторами. Заключение.Таким образом, применение полиненасыщенных жирных кислот приводит к снижению смертности от ИБС.

Aim. A meta-analysis was undertaken to sum up data on long-chain polyunsaturated fatty acids treatment and coronary deaths. Methods. Only studies with no less than 500 participants and length of follow-up no less than one year were included. Total number of studies was 13 with 127455 participants. Results. Fixed factor (Peto) model demonstrated significant decrease in cardiac deaths in polyunsaturated fatty acids -treated group. (OR=0,89, 95%CI: 0,83-0,95, р=0,001). Random factor model confidence interval also does not included one (OR=0,88, 95%CI: 0,80-0,97, p=0.008). Subgroup analysis of studies that used therapy with 460 mg eicosapentaenoic acid and 380 docosahexaenoic acid per day demonstrated significant reduction in cardiac deaths (OR=0,84, 95%CI: 0,77-0,92) in both fixed factor and random factor models. Conclusion. Correspondingly supplementation with polyunsaturated fatty acids associated with lower coronary mortality.

Ишемическая болезнь сердцаполиненасыщенные жирные кислотымета-анализCoronary heart diseasepolyunsaturated fatty acidsmeta-analysisнетnoReferencesASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G et al. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. The New England Journal of Medicine. 2018;379(16):1540–50. DOI: 10.1056/NEJMoa1804989ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G et al. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. The New England Journal of Medicine. 2018;379(16):1540–50. DOI: 10.1056/NEJMoa1804989Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L et al. Associations of Omega-3 Fatty Acid Supplement Use with Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals. JAMA Cardiology. 2018;3(3):225–34. DOI: 10.1001/jamacardio.2017.5205Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L et al. Associations of Omega-3 Fatty Acid Supplement Use with Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals. JAMA Cardiology. 2018;3(3):225–34. DOI: 10.1001/jamacardio.2017.5205Maki KC, Palacios OM, Bell M, Toth PP. Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps. Journal of Clinical Lipidology. 2017;11(5):1152-1160.e2. DOI: 10.1016/j.jacl.2017.07.010Maki KC, Palacios OM, Bell M, Toth PP. Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps. Journal of Clinical Lipidology. 2017;11(5):1152-1160.e2. DOI: 10.1016/j.jacl.2017.07.010Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events: A Systematic Review and Metaanalysis. JAMA. 2012;308(10):1024–33. DOI: 10.1001/2012.jama.11374Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events: A Systematic Review and Metaanalysis. JAMA. 2012;308(10):1024–33. DOI: 10.1001/2012.jama.11374Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2018;7:CD003177. DOI: 10.1002/14651858.CD003177.pub3Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2018;7:CD003177. DOI: 10.1002/14651858.CD003177.pub3Bowen KJ, Harris WS, Kris-Etherton PM. Omega-3 Fatty Acids and Cardiovascular Disease: Are There Benefits? Current Treatment Options in Cardiovascular Medicine. 2016;18(11):69. DOI: 10.1007/s11936-016-0487-1Bowen KJ, Harris WS, Kris-Etherton PM. Omega-3 Fatty Acids and Cardiovascular Disease: Are There Benefits? Current Treatment Options in Cardiovascular Medicine. 2016;18(11):69. DOI: 10.1007/s11936-016-0487-1Maki K, Dicklin M. Omega-3 Fatty Acid Supplementation and Cardiovascular Disease Risk: Glass Half Full or Time to Nail the Coffin Shut? Nutrients. 2018;10(7):E864. DOI: 10.3390/nu10070864Maki K, Dicklin M. Omega-3 Fatty Acid Supplementation and Cardiovascular Disease Risk: Glass Half Full or Time to Nail the Coffin Shut? Nutrients. 2018;10(7):E864. DOI: 10.3390/nu10070864Плавинский С.Л., Баринова А.Н. Использование препарата высококонцентрированных этиловых эфиров полиненасыщенных жирных кислот в профилактике осложнений после перенесенного инфаркта миокарда. анализ стоимость-полезность. Кардиология. 2018;58(2):77–82. DOI: 10.18087/cardio.2018.2.10089Plavinskii S.L., Barinova A.N. Use of Highly Concentrated Polyunsaturated Fatty Acids for Prevention of Complications After Myocardial Infarction. Cost-Utility Analysis. Kardiologiia. 2018;58(2):77–82. DOI: 10.18087/cardio.2018.2.10089Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet (London, England). 1999;354(9177):447–55. PMID: 10465168Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet (London, England). 1999;354(9177):447–55. PMID: 10465168Manson JE, Cook NR, Lee I-M, Christen W, Bassuk SS, Mora S et al. Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. New England Journal of Medicine. 2019;380(1):23–32. DOI: 10.1056/NEJMoa1811403Manson JE, Cook NR, Lee I-M, Christen W, Bassuk SS, Mora S et al. Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. New England Journal of Medicine. 2019;380(1):23–32. DOI: 10.1056/NEJMoa1811403Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. The New England Journal of Medicine. 2019;380(1):11–22. DOI: 10.1056/NEJMoa1812792Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. The New England Journal of Medicine. 2019;380(1):11–22. DOI: 10.1056/NEJMoa1812792Schwarzer G. Meta: An R package for meta-analysis. R News. 2007;7(3):40–5. [Av. at: https://cran.rstudio.org/doc/Rnews/Rnews_2007-3.pdf#page=40]Schwarzer G. Meta: An R package for meta-analysis. R News. 2007;7(3):40–5. [Av. at: https://cran.rstudio.org/doc/Rnews/Rnews_2007-3.pdf#page=40]Einvik G, Ole Klemsdal T, Sandvik L, Hjerkinn EM. A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk. European Journal of Cardiovascular Prevention & Rehabilitation. 2010;17(5):588–92. DOI: 10.1097/HJR.0b013e328339cc70Einvik G, Ole Klemsdal T, Sandvik L, Hjerkinn EM. A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk. European Journal of Cardiovascular Prevention & Rehabilitation. 2010;17(5):588–92. DOI: 10.1097/HJR.0b013e328339cc70Bonds DE, Harrington M, Worrall BB, Bertoni AG, Eaton CB, Hsia J et al. Effect of Long-Chain ω-3 Fatty Acids and Lutein + Zeaxanthin Supplements on Cardiovascular Outcomes: Results of the AgeRelated Eye Disease Study 2 (AREDS2) Randomized Clinical Trial. JAMA Internal Medicine. 2014;174(5):763–71. DOI: 10.1001/jamainternmed.2014.328Bonds DE, Harrington M, Worrall BB, Bertoni AG, Eaton CB, Hsia J et al. Effect of Long-Chain ω-3 Fatty Acids and Lutein + Zeaxanthin Supplements on Cardiovascular Outcomes: Results of the AgeRelated Eye Disease Study 2 (AREDS2) Randomized Clinical Trial. JAMA Internal Medicine. 2014;174(5):763–71. DOI: 10.1001/jamainternmed.2014.328Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010;341:c6273. DOI: 10.1136/bmj.c6273Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010;341:c6273. DOI: 10.1136/bmj.c6273Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients ( JELIS): a randomised open-label, blinded endpoint analysis. The Lancet. 2007;369(9567):1090–8. DOI: 10.1016/S0140-6736(07)60527-3Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients ( JELIS): a randomised open-label, blinded endpoint analysis. The Lancet. 2007;369(9567):1090–8. DOI: 10.1016/S0140-6736(07)60527-3Kromhout D, Giltay EJ, Geleijnse JM. n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction. New England Journal of Medicine. 2010;363(21):2015–26. DOI: 10.1056/NEJMoa1003603Kromhout D, Giltay EJ, Geleijnse JM. n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction. New England Journal of Medicine. 2010;363(21):2015–26. DOI: 10.1056/NEJMoa1003603Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H et al. OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction. Circulation. 2010;122(21):2152–9. DOI: 10.1161/CIRCULATIONAHA.110.948562Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H et al. OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction. Circulation. 2010;122(21):2152–9. DOI: 10.1161/CIRCULATIONAHA.110.948562The Risk and Prevention Study Collaborative Group. n–3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors. New England Journal of Medicine. 2013;368(19):1800–8. DOI: 10.1056/NEJMoa1205409The Risk and Prevention Study Collaborative Group. n–3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors. New England Journal of Medicine. 2013;368(19):1800–8. DOI: 10.1056/NEJMoa1205409GISSI-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. The Lancet. 2008;372(9645):1223–30. DOI: 10.1016/S0140-6736(08)61239-8GISSI-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. The Lancet. 2008;372(9645):1223–30. DOI: 10.1016/S0140-6736(08)61239-8The ORIGIN Trial Investigators. n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. New England Journal of Medicine. 2012;367(4):309–18. DOI: 10.1056/NEJMoa1203859The ORIGIN Trial Investigators. n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. New England Journal of Medicine. 2012;367(4):309–18. DOI: 10.1056/NEJMoa1203859

The authors declare that there are no conflicts of interest present.